000			05229nam a22003974i 4500
001			013731502
003			‫‪EG-GaU‬‬
005			20210706125311.0
008			061106s2007 it a b 001 0 eng c
010			_a 2006938039
020			_a9788847004917
020			_a8847004918
040			_aNLM _beng _erda _cNLM _dOHX _dC3L _dBAKER _dYDXCP _dDLC _dUk _dEG-GaU
041	1		_aeng _hita
082	0	4	_223 _a610.72 _bB.A.F.
100	1		_aBacchieri, Antonella, _eauthor _9858
240	1	0	_aFondamenti di ricerca clinica _lEnglish
245	1	0	_aFundamentals of clinical research : _bbridging medicine, statistics, and operations / _cAntonella Bacchieri, Giovanni Della Cioppa.
264		1	_aMilano : _bSpringer, _c[2007]
264		4	_c©2007
300			_axxv, 343 pages : _billustrations ; _c25 cm
336			_atext _2rdacontent _btxt
337			_aunmediated _2rdamedia _bn
338			_avolume _2rdacarrier _bnc
490	1		_aStatistics for biology and health
504			_aIncludes bibliographical references (pages [331]-335) and index.
505	0		_a 1. Variability of Biological Phenomena and Measurement Errors1.1. Phenotypic Variability 1.2. Temporal Variability.1.3. Measurement - Related Variability 1.3.1. The Measurement 1.3.2. Measurement Errors 1.4. Variability of Diagnostic Tests Summary 2. Distinctive Aspects of a Biomedical Study. Observational and Experimental Studies 2.1. Distinctive Features of Biomedical Studies 2.2. The Study Protocol 2.3. Observational Studies2.4. Experimental StudiesSummary 3. Observational Studies3.1. Basic Designs of Observational Studies 3.1.1. Prospective or Cohort Studies3.1.2. Retrospective Studies or Control Cases 3.1.3. Sample Size3.2. Bias and Confounding 3.2.1. Control of Bias in Epidemiology 3.2.2. Control of the Phenomenon of Confounding |3.3. Advantages and Disadvantages of the Different Types of Observational Studies Summary 4 Defining the Treatment Effect 4.1. From the Single Measurement to the Signal 4.2. Identification and Quantification of the End-Points (Individual Subject Level)4.2.1. Methodological Characteristics of the End-Point 4.2.2 Discriminating Between Primary and Secondary End-Points and Between Efficacy and Safety/Tolerability End-Points 4.3. Identification and Quantification of the Signals (Group Level) 4.4. Statistical Considerations 4.5. Practical, Regulatory, Marketing and Pharmaco-Economic Considerations 4.6. Selection and Characterization of the Primary End-Point and Signal: an Example 4.6.1. Stage One: Define the Main Therapeutic Level 4.6.2. Stage Two: Define the Primary End-Point (Individual Patient Level) 4.6.3. Stages Three and Four: Define the Group Indicator, the Signal, and the Threshold of Clinical Relevance (Treatment Group and Study Levels) 4.7. More Than One Question in the Same Study: the Problem of Multiple Statistical Tests 4.8. Validation of Measurement Scales 4.9. Special Types of End-Points Summary 5. Probability, Inference and Decision Making 5.1. Probability 5.1.1 Definitions 5.1.2. Probability Distribution and Probability Density Function5.1.3. Normal or Gaussian Distribution5.2. Basic Concepts of Inference 5.2.1. Hypothesis Testing and Statistical Formulation of the Medical Question 5.2.2. Statistical Estimation as the Tool for Evaluation of Clinical Relevance 5.3. Statistical Inference in the Frequentist and the Bayesian Approaches5.4. Two Digressions: Measures of Variability and Likelihood Function 5.4.1. Measures of Variability5.4.2. Likelihood Function 5.5. Frequentist (Classical) Analysis of a Clinical Trial 5.5.1. Hypothesis Testing: the Frequentist Solution5.5.2. Estimation of the Effect: the Frequentist Solution 5.6. Bayesian Analysis of a Clinical Trial 5.6.1. Hypothesis Testing: the Bayesian Solution 5.6.2. Estimation of the Effect: the Bayesian Solution5.7. Some Additional Considerations on the Frequentist and Bayesian Approaches 5.8. Parametric and Non-Parametric Inference5.9. Statistical Decision Making in the Medical Field 5.10. Evidence-Based Medicine Summary 6. The Choice of the Sample 6.1. Which Subjects Should Form the Sample? 6.1.1. Characteristics of the Patients to be Enrolled in the Study6.1.2. Mechanism of Subject Selection 6.2. How Many Subjects Should Form the Sample? 6.2.1. Statistical Considerations 6.2.2. Medical and Practical AspectsSummary 7. The Choice of Treatments 7.1. Study Treatments7.1.1. How Many Treatments 7.1.2. What Treatments7.1.3. Blinding of the Study Treatments 7.1.4. Packaging and Logistics7.2. Concomitant TreatmentsSummary 8. Experimental Design: Fallacy of 'Before-After' Compa.
520			_aHere is a new book on methods and issues in clinical research. Integrate medical and statistical components of clinical research. Give space to the ethical implications of methodological issues in clinical research. The book ends with a brief description of the drug development process and the phases of clinical development.
650		7	_aMedicine _xResearch. _9859 _2GU-sh
650	1	7	_aBiomedical Research _xmethods. _9860 _2GU-sh
650	2	7	_aResearch Design. _9861 _2GU-sh
700	1		_aDella Cioppa, Giovanni. _9862
830		0	_aStatistics for biology and health. _9863
942			_cBK _2ddc
999			_c321 _d321